Goldenrod Therapeutics, Inc.
Houston, US · Founded 2023 · Texas corporation · 1 known investors
Find your way into Goldenrod Therapeutics, Inc.
227 people in our graph share verified history with the Goldenrod Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.
Somnathunlockedknows Dev Chatterjee · together at Indian Institute of Technology, Kharagpur (overlapped)
knows the team · via Indian Institute of Technology, Kharagpur
×6knows the team · via Stanford University Graduate School of Business
×3knows the team · via University of Notre Dame
knows the team · via MD Anderson Cancer Center
Goldenrod Therapeutics develops brain-penetrant phosphodiesterase 4 inhibitors for neurological and neuropsychiatric disorders, focusing on overcoming tolerability limitations of earlier PDE4 inhibitors to address neuroinflammation.
Founders & leadership
Goldenrod Therapeutics, Inc. was founded in 2023 by Corey Hopkins.
CH
Corey HopkinsChair of the Department of Pharmaceutical Sciences and Director of the Center for Drug Design and Innovation at UNMC
DC
Dev ChatterjeeinExecutiveDev Chatterjee is an executive officer at Goldenrod Therapeutics, a company developing phosphodiesterase 4 inhibitors for neurological and neuropsychiatric disorders. He has experience in biomedical commercialization and de-risking early-stage therapeutic innovations from academic sources.
LL
Leo Linbeck IVExecutive
MW
Board
AV
Atul VaradhacharyBoard director
LL
TB
Thomas BrenninkmeijerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$3.2M disclosed across 1 round · 2026
▶$3.2MraisedJun 2026 · 2 investors · BiotechnologyRule 506(b)
▶$3.2MraisedJun 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dev ChatterjeeExecutive Officer
- Leo Linbeck IVExecutive Officer
- Mark WorschehExecutive Officer, Director
- Atul VaradhacharyExecutive Officer, Director
- Leo Linbeck IIIDirector
- Thomas BrenninkmeijerDirector
- Offering amount
- $6.5M
- Amount sold
- $3.2M
- Minimum investment
- $100K
- First sale
- May 2026
- Incorporated
- Corporation, Texas, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Goldenrod Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Goldenrod Therapeutics raises $6.5 million to test UNMC-created drug that could change modern medicine - Silicon Prairie Newssiliconprairienews.com · Jul 2026
Goldenrod Therapeutics, Fannin Partners secures $6.5M for FA drug study - InnovationMaphouston.innovationmap.com · Jun 2026
Goldenrod Therapeutics Holds Initial Close of $6.5M Seed Fundingfinsmes.com · Jun 2026Frequently asked questions
- What does Goldenrod Therapeutics, Inc. do?
- Goldenrod Therapeutics develops brain-penetrant phosphodiesterase 4 inhibitors for neurological and neuropsychiatric disorders, focusing on overcoming tolerability limitations of earlier PDE4 inhibitors to address neuroinflammation.
- Who founded Goldenrod Therapeutics, Inc.?
- Goldenrod Therapeutics, Inc. was founded by Corey Hopkins in 2023.
- Who are Goldenrod Therapeutics, Inc.'s investors?
- Goldenrod Therapeutics, Inc.'s investors include Fannin Goldenrod Holdings.
- How much funding has Goldenrod Therapeutics, Inc. raised?
- Goldenrod Therapeutics, Inc. has disclosed $3.2M raised across 1 round.
- Where is Goldenrod Therapeutics, Inc. headquartered?
- Goldenrod Therapeutics, Inc. is headquartered in Houston, US.